Insider Activity
$4814.3T buy / $0.00 sell
REEMF
RARE ELEMENT RESOURCES LTD
$0.7700 ▼ -4.94%
Prev close $0.8100Insider Buying Cluster (2 insiders) Materials & Mining
Snapshot
The big-picture read on REEMF right now — valuation, ownership and activity at a glance.
Insider Net $
$4814.3T
Social Sentiment
50° Neutral
SEC Reports
1
Price chart 30d -20.6%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 28, 2026 Event
EMCITATE
Original Approval — Type 1 - New Molecular Entity — TABLET
Aug 12, 2026 earnings_calendar
Jul 13, 2026 SEC REEMF Q2 2026 Earnings Scheduled — 2026-08-12
Rare Element Resources Ltd. filed definitive additional proxy materials (DEFA14A) for its 2026 Annual Meeting scheduled
DEFA14A — Impact 2/10
Mar 10, 2026 Insider
Synchron bought 100,149,060 shares
10%+ Owner @ $24,035,774.40 ($2407.2T)
Mar 10, 2026 Insider
BLUE JAMES N bought 100,149,060 shares
10%+ Owner @ $24,035,774.40 ($2407.2T)
Mar 4, 2026 Insider
HICKEY PAUL JOSEPH was granted 250 shares
Director @ $0.2400 ($60.00)
Social media sentiment
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
50°
Neutral
BearishNeutralBullish
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
1 SEC filing reports analyzed · 0 bullish, 0 bearish, 0 mixed, 1 neutral · avg impact 2.0/10.
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 28, 2026
FDA
EMCITATE
Original Approval — Type 1 - New Molecular Entity — TABLET
Aug 12, 2026
earnings_calendar
REEMF Q2 2026 Earnings Scheduled — 2026-08-12
Aug 4, 2026
earnings_calendar
REEMF Q2 2026 Earnings Scheduled — 2026-08-04
May 19, 2026
earnings_calendar
REEMF Q1 2026 Earnings Scheduled — 2026-05-19
Apr 8, 2026
Clinical Trial
Withdrawal of Tiratricol Treatment in Males With Monocarboxylate Transporter 8 Deficiency (MCT8 Deficiency)
Phase Phase 3 — COMPLETED
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00–$0.00 | — | — | — | $0.0B | — |
| Next Q | $0.00 | $0.00–$0.00 | — | — | — | $0.0B | — |
| Current FY | $0.00 | $0.00–$0.00 | — | — | — | $0.0B | — |
| Next FY | $0.00 | $0.00–$0.00 | — | — | — | $0.0B | — |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
4 insiders, 7 transactions. Net $4814.3T — $4814.3T bought, $0.00 sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Mar 10, 2026 | Synchron | 10%+ Owner | BUY | 100,149,060 | $24,035,774.40 | $2407.2T |
| Mar 10, 2026 | BLUE JAMES N | 10%+ Owner | BUY | 100,149,060 | $24,035,774.40 | $2407.2T |
| Mar 4, 2026 | HICKEY PAUL JOSEPH | Director | AWARD | 250 | $0.2400 | $60.00 |
| Mar 4, 2026 | Grandey Gerald W | Director | AWARD | 1,250,000 | $0.2400 | $300.0K |
| Mar 4, 2026 | HICKEY PAUL JOSEPH | Director | AWARD | 6,250 | $0.2400 | $1.5K |
| Mar 4, 2026 | HICKEY PAUL JOSEPH | Director | AWARD | 6,940 | $0.2400 | $1.7K |
| Mar 4, 2026 | HICKEY PAUL JOSEPH | Director | AWARD | 277 | $0.2400 | $66.48 |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for REEMF.
Shares short
1,646,325
Settlement Sep 15, 2026
Change vs prior
-12.7%
Semi-monthly cycle
Days to cover
1.9
At avg daily volume
All REEMF filing & press-release reports (1)
- DEFA14A reportJul 13, 2026